2-色满羰基氯化物 | 227466-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 2-色满羰基氯化物
• 中文别名: 咪唑并[5,1-f][1,2,4]三嗪,5-甲基-2-(甲磺酰)-7-苯基-
• 英文名称: (R)-chroman-2-carboxylic acid chloride
• 英文别名: (-)-(R)-3,4-dihydro-2H-1-benzopyran-2-carbonyl chloride；(2R)-3,4-Dihydro-2H-1-benzopyran-2-carbonyl chloride；(2R)-3,4-dihydro-2H-chromene-2-carbonyl chloride
• CAS: 227466-91-3
• 化学式: C₁₀H₉ClO₂
• 分子量: 196.633
• InChiKey: UXOHRZNOVPCNMD-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-色满羰基氯化物 在 吡啶 、 ammonium hydroxide 、 dimethyl sulfide borane 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 生成 N-[(2R)-3,4-dihydro-2H-chromen-2-ylmethyl]-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  旋光的6-取代的2-（氨基甲基）苯并二氢吡喃的合成

  摘要：

  从容易获得的苯并二氢吡喃2-羧酸前体合成了三种新型的旋光的6-取代的2-（氨基甲基）苯并吡喃。这些含苯并二氢吡喃的伯胺是合成苯并二氢吡喃衍生物的有用试剂。

  DOI：

  10.1016/j.tetlet.2004.05.037
• 作为产物：
  描述：

  色酮-2-甲酸 在 氯化亚砜 、 palladium 10% on activated carbon 、 (R)-(+)-1-苯丙胺 、 氢气 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 甲基叔丁基醚 、 水 、 1,2-二氯乙烷 、 乙腈 为溶剂， 20.0 ℃ 、413.7 kPa 条件下， 反应 8.0h， 生成 2-色满羰基氯化物
  参考文献：
  名称：

  [EN] SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS
  [FR] COMPOSÉS SUBSTITUÉS DE CHROMANE EN TANT QUE MODULATEURS DES RÉCEPTEURS DE DÉTECTION DU CALCIUM

  摘要：

  本发明提供了钙感应受体调节剂（CaSR）。特别是，本发明的化合物可用于治疗、管理和/或减轻与钙感应受体（CaSR）调节相关的疾病、障碍、综合征和/或症状。本发明还提供了其药物组合物，以及用于治疗、管理和/或减轻与CaSR调节相关的疾病、障碍、综合征和/或症状的方法。本发明还涉及用于制备本发明化合物的过程。

  公开号：

  WO2013124828A1

文献信息

• (Benzodioxan, benzofuran or benzopyran) derivatives having fundic
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06133277A1

  公开（公告）日：2000-10-17

  The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk.sup.1 is C.sub.1-6 alkanediyl optionally substituted with hydroxy, C.sub.1-4 alkyloxy or C.sub.1-4 alkylcarbonyloxy; --Z.sup.1 --Z.sup.2 -- is a bivalent radical; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, C.sub.1-6 alkyl, hydroxy, halo and the like; or when R.sup.1 and R.sup.2 are on adjacent carbon atoms, R.sup.1 and R.sup.2 taken together may form a bivalent radical; R.sup.4 is hydrogen or C.sub.1-6 alkyl; A is a bivalent radical of formula --NR.sup.6 --Alk.sup.2 -- (b-1), or --Npiperidinyl--(CH.sub.2).sub.m (b-2) wherein m is 0 or 1; R.sup.5 is a radical of formula ##STR1## wherein n is 1 or 2; p.sup.1 is 0, and p.sup.2 is 1 or 2; or p.sup.1 is 1 or 2, and p.sup.2 is 0; X is oxygen, sulfur or .dbd.NR.sup.9 ; Y is oxygen or sulfur; R.sup.7 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl or phenylmethyl; R.sup.8 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl phenyl or phenylmethyl; R.sup.9 is cyano, C.sub.1-6 alkyl, C.sub.3-6 cyclo-alkyl, C.sub.1-6 alkyloxycarbonyl or aminocarbonyl; R.sup.10 is hydrogen or C.sub.1-6 alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

  本发明涉及化合物的公式(I)，其立体化学异构体形式，N-氧化物形式或药物可接受的酸加成盐形式，其中Alk.sup.1是C.sub.1-6烷二基可选地被羟基，C.sub.1-4烷氧基或C.sub.1-4烷基羧酸基取代; --Z.sup.1 --Z.sup.2 --是一个二价基团; R.sup.1，R.sup.2和R.sup.3各自独立地选择自氢，C.sub.1-6烷基，羟基，卤素等; 或者当R.sup.1和R.sup.2在相邻的碳原子上时，R.sup.1和R.sup.2可以组成一个二价基团; R.sup.4是氢或C.sub.1-6烷基; A是公式--NR.sup.6--Alk.sup.2--(b-1)或--Npiperidinyl--(CH.sub.2).sub.m (b-2)的二价基团，其中m为0或1; R.sup.5是公式##STR1##的基团，其中n为1或2; p.sup.1为0，p.sup.2为1或2; 或者p.sup.1为1或2，p.sup.2为0; X是氧，硫或.dbd.NR.sup.9; Y是氧或硫; R.sup.7是氢，C.sub.1-6烷基，C.sub.3-6环烷基，苯基或苯甲基; R.sup.8是C.sub.1-6烷基，C.sub.3-6环烷基，苯基或苯甲基; R.sup.9是氰基，C.sub.1-6烷基，C.sub.3-6环烷基，C.sub.1-6烷氧羰基或氨基羰基; R.sup.10是氢或C.sub.1-6烷基; Q是一个二价基团。公开了制备所述产品的过程，包含所述产品的制剂以及其作为药物的用途，特别是用于治疗与胃底松弛受损相关的疾病。
• [EN] (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES HAVING FUNDIC RELAXATION PROPERTIES<br/>[FR] DERIVES (DE BENZODIOXANE, DE BENZOFURANE OU DE BENZOPYRANE) POSSEDANT DES PROPRIETES DE RELACHEMENT FUNDIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO1999029687A1

  公开（公告）日：1999-06-17

  The present invention of compounds of formula (I), a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk1 is C¿1-6?alkanediyl optionally substituted with hydroxy, C1-4alkyloxy or C1-4alkylcarbonyloxy; -Z?1-Z2¿- is a bivalent radical; R?1, R2 and R3¿ are each independently selected from hydrogen, C¿1-6?alkyl, hydroxy, halo and the like; or when R?1 and R2¿ are on adjacent carbon atoms, R?1 and R2¿ taken together may form a bivalent radical; R4 is hydrogen or C¿1-6?alkyl; A is a bivalent radical of formula -NR?6-Alk2¿-(b-1), or -Npiperidinyl-(CH¿2?)m(b-2) wherein m is 0 or 1; R?5¿ is a radical of formula (A), wherein n is 1 or 2; p1 is 0, and p2 is 1 or 2; or p1 is 1 or 2, and p2 is 0; X is oxygen, sulfur or =NR9; Y is oxygen or sulfur; R7 is hydrogen, C¿1-6?alkyl, C3-6cycloalkyl, phenyl or phenylmethyl; R?8¿ is C¿1-6?alkyl, C3-6cycloalkyl phenyl or phenylmethyl; R?9¿ is cyano, C¿1-6?alkyl, C3-6cycloalkyl, C1-6alkyloxycarbonyl or aminocarbonyl; R?10¿ is hydrogen or C¿1-6?alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

  本发明涉及化合物的公式（I），其立体化学异构体形式，其N-氧化物形式或其药学上可接受的酸加成盐，其中Alk1是C1-6烷基二亚基，可选地取代羟基，C1-4烷氧基或C1-4烷基羰氧基; -Z1-Z2-是双价基团; R1，R2和R3分别独立地选自氢，C1-6烷基，羟基，卤素等; 或当R1和R2在相邻的碳原子上时，R1和R2结合在一起可以形成一个双价基团; R4是氢或C1-6烷基; A是公式-NR6-Alk2-(b-1)或-N哌啶基-(CH2)m(b-2)的双价基团，其中m为0或1; R5是公式（A）的基团，其中n为1或2; p1为0，p2为1或2; 或p1为1或2，p2为0; X是氧，硫或= NR9; Y是氧或硫; R7是氢，C1-6烷基，C3-6环烷基，苯基或苯甲基; R8是C1-6烷基，C3-6环烷基，苯基或苯甲基; R9是氰基，C1-6烷基，C3-6环烷基，C1-6烷氧羰基或氨基羰基; R10是氢或C1-6烷基; Q是双价基团。本发明还公开了制备所述产品的方法，包含所述产品的制剂以及它们作为药物的用途，特别是用于治疗与胃底松弛障碍有关的疾病。
• (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
  申请人：——

  公开号：US20030083365A1

  公开（公告）日：2003-05-01

  The present invention of compounds of formula (I) 1 a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk 1 is C 1-6 alkanediyl optionally substituted with hydroxy, C 1-4 alkyloxy or C 1-4 alkylcarbonyloxy; -Z 1 -Z 2 - is a bivalent radical; R 1 , R 2 and R 3 are each independently selected from hydrogen, C 1-6 alkyl, hydroxy, halo and the like; or when R 1 and R 2 are on adjacent carbon atoms, R 1 and R 2 taken together may form a bivalent radical; R 4 is hydrogen or C 1-6 alkyl; A is a bivalent radical of formula —NR 6 —Alk 2 - (b- 1 ), or —Npiperidinyl-(CH 2 ) m (b- 2 ) wherein m is 0 or 1; R 5 is a radical of formula 2 wherein n is 1 or 2; p 1 is 0, and p 2 is 1 or 2; or p 1 is 1 or 2, and p 2 is 0; X is oxygen, sulfur or ═NR 9 ; Y is oxygen or sulfur; R 7 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, phenyl or phenylmethyl; R 8 is C 1-6 alkyl, C 3-6 cycloalkyl phenyl or phenylmethyl; R 9 is cyano, C 1-6 alkyl, C 3-6 cyclo-alkyl, C 1-6 alkyloxycarbonyl or aminocarbonyl; R 10 is hydrogen or C 1-6 alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

  本发明涉及以下化合物的配方(I)1a立体化学异构体形式、其N-氧化物形式或其药学上可接受的酸加成盐，其中Alk1是C1-6烷基二亚甲基，可选地被羟基、C1-4烷氧基或C1-4烷基羧酸酯取代；-Z1-Z2-是双价基团；R1、R2和R3各自独立地选自氢、C1-6烷基、羟基、卤素等；或当R1和R2在相邻的碳原子上时，R1和R2可以一起形成一个双价基团；R4是氢或C1-6烷基；A是式—NR6—Alk2-(b-1)或—N哌啶基-(CH2)m(b-2)的双价基团，其中m为0或1；R5是式2的基团，其中n为1或2；p1为0，p2为1或2；或p1为1或2，p2为0；X是氧、硫或═NR9；Y是氧或硫；R7是氢、C1-6烷基、C3-6环烷基、苯基或苯基甲基；R8是C1-6烷基、C3-6环烷基、苯基或苯基甲基；R9是氰基、C1-6烷基、C3-6环烷基、C1-6烷氧羰基或氨基羰基；R10是氢或C1-6烷基；Q是双价基团。本发明还公开了制备所述产品的方法、包含所述产品的配方以及它们作为药物的用途，特别是用于治疗与胃底松弛障碍有关的疾病。
• WO2007/123941
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of LNP1892: A Precision Calcimimetic for the Treatment of Secondary Hyperparathyroidism
  作者：Manojkumar R. Shukla、Gayathri Sadasivam、Ankush Sarde、Majid Sayyed、Vipul Pachpute、Ramesh Phadtare、Navanath Walke、Vinod D. Chaudhari、Rajesh Loriya、Talha Khan、Ganesh Gote、Chetan Pawar、Mahadeo Tryambake、Nilesh Mahajan、Amruta Gandhe、Sudeep Sabde、Shashikant Pawar、Vinod Patil、Dipak Modi、Maneesh Mehta、Prashant Nigade、Vijay Modak、Ravindra Ghodke、Lakshmi Narasimham、Mandar Bhonde、Jayasagar Gundu、Rajan Goel、Chirag Shah、Sanjeev Kulkarni、Sharad Sharma、Dhananjay Bakhle、Rajender Kumar Kamboj、Venkata P. Palle

  DOI：10.1021/acs.jmedchem.3c00698

  日期：2023.7.27